

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health & Family Welfare, Govt. of India
Sector-23, Raj Nagar, Ghaziabad – 201002

Minutes of the 59th Meeting of the Scientific Body of IPC

Date of Meeting: January 19, 2026

Chairperson: Dr. V. M. Katoch

The list of participants is appended as **Enclosure-I**.

Welcome and Opening of the Meeting

The 59th meeting of the IPC Scientific Body began with opening remarks by Dr. V. M. Katoch, Chairperson of the Scientific Body, IPC. Thereafter, the main agenda was presented in the following sequence, and the decisions of the Scientific Body were recorded as follows:

Item 1. Introduction and Brief Presentation by the Member Secretary

Dr. V. Kalaiselvan, Member Secretary, presented the progress and key achievements made by the Indian Pharmacopoeia Commission since the last meeting of the Scientific Body.

The Scientific Body noted and appreciated the progress made by IPC in various key domains, including publication-related activities and implementation of IP 2026, strengthening of stakeholder outreach and engagement, expansion of quality-related scientific work, and continuous efforts towards international recognition and harmonization initiatives.

Item 2. Confirmation of the Minutes of the 58th Meeting of the SB held on September 04, 2025

Confirmed by the Scientific Body.

Item 3. Action Taken Report on the Minutes of the 58th Meeting of the SB held on September 04, 2025

Noted by the Scientific Body.

MAIN AGENDA

Item 4. Progress of AR&D Division

The Scientific Body reviewed the progress of the AR&D Division with respect to the publication of IP 2026 and its online version, activities related to the international recognition of the IP, IPC's participation in the Pharmacopoeial Discussion Group (PDG), meetings of the Expert Working Group (EWG), and stakeholders' conferences and webinars.

Development of new monographs and upgradations of monographs with respect to dissolution and osmolarity specifications for the forthcoming IP Addendum 2028 were also noted.

It was suggested to explore the possibility of including a monograph on “Water for Dialysis”. Further, monograph proposals from the countries that have recognized the IP may also be explored.

Item 5. Progress of Microbiology Division

The Scientific Body noted the progress made by the Microbiology Division with respect to the development of a new general chapter (Disinfectants and Antiseptics), and work related to the upgradation of general chapter and monographs for the Indian Pharmacopoeia.

The Scientific Body also noted the progress made by the Division with respect to analytical testing, proficiency testing programme as per ISO/IEC 17043:2023 in the biological domain, and research publications.

Item 6. Progress of the Biologics Section

The Scientific Body noted and approved the proposal for amendment approved in respective expert working group meetings (Annexure-5) to be published in amendment list-01 to IP 2026

The Scientific Body noted the work progress of the Biologics Division regarding development and upgradation of General Chapters and monographs of biologicals for Veterinary and human use for the IP 2026, EWG, and stakeholders’ meetings, analytical testing, international participation, training of IPC officials, and students.

Scientific body member noted and appreciated the detailed roadmap plan & initiatives taken to create awareness about Blood and Blood Components monographs included in edition IP 2026.

Regarding IPC's proposal on Notified Central Drugs Laboratory w.r.t. biologically derived Pharmaceuticals, it was suggested to constitute an expert group to review the proposal.

Item 7. National Formulary of India (NFI) - 7th Edition

The Scientific Body noted and appreciated the work progress of the NFI 2026.

Item 8. Progress of Reference Standard Division (RSD)

The Scientific Body noted the progress made by the Division in the development of new IPRS and impurity standards, updates related to lot changes in reference standards, drug analysis, and revenue generation.

Item 9. Progress of Quality Assurance (QA) Division

The Scientific Body noted the considerable progress achieved by the Division in maintaining accreditation certifications in accordance with ISO standards. This progress encompasses the execution of proficiency testing (PT) programs, methodical internal quality evaluations, and the provision of extensive training for students.

Item 10. Progress of the Phytopharmaceuticals Division

As per the recommendations of the Scientific Body on regulations regarding phytopharmaceuticals, Schedule M of the Drugs and Cosmetics Act 1940 and Rules 1945 need to be reviewed and, if necessary, amended to better categorize phytopharmaceuticals. In response, the Chairperson advised establishing a committee to collaborate with the CDSCO to address these concerns. It was acknowledged that revisiting Schedule M is crucial for the successful integration of phytopharmaceuticals within the current regulatory framework.

Furthermore, based on valuable input from Scientific Body experts, there is optimism that stakeholders will gain a clearer understanding of the roles and objectives outlined in the Phytopharmaceuticals Ingredients

Monograph. The scientific body experts reiterated the importance of continuing to develop monographs on Phytopharmaceutical Ingredients in upcoming editions of the Indian Pharmacopoeia (IP). The chairperson also suggested reaching a consensus to propose ten (10) priority new Phytochemical Reference Substances, which will benefit both current PPI monographs and those in development.

Item 11. Progress of Pharmacovigilance Programme of India (PvPI)

The Scientific Body noted the progress of PvPI for reporting of Adverse Drug Reactions (ADR), expansion of ADR Monitoring Centres across India, issuing drug safety alerts, and stakeholders' meetings.

Item 12. Progress of the Materiovigilance Programme of India (MvPI)

The Scientific Body members noted with appreciation the progress made by the Materiovigilance Programme of India (MvPI) and the WHO Collaborating Centre (WHO-CC).

Item 13. Progress of Medical Devices Division

The progress of the Medical Devices Division was noted by the Scientific Body with respect to the establishment of the Medical Devices Division, the development of medical device monographs, and the certification services.

Item 14. National/International Mutual Cooperations (MoU)

Noted by the Scientific Body.

Item 15. Progress of Publication Division

Approved and noted by the Scientific Body.

Item 16. Revenue Generation

Noted by the Scientific Body.

Item 17. Any Other Item with the Permission of the Chairperson

The Scientific Body enquired and noted the update about the progress of consideration of the assessment promotion scheme for scientific staff, as well as the signing of the MoU with SMU, Lucknow.

The meeting ended with a vote of thanks to the Chairperson and Members of the Scientific Body of IPC by the Member Secretary.

List of Scientific Body Members Participated

1. Dr. V. M. Katoch, Former DG-ICMR cum Secretary-Department of Health Research and Chairperson, Scientific Body-IPC (connected through VC)
2. Prof. Sanjay Singh, Vice Chancellor, Dr Shakuntala Misra University (SMU), Lucknow (connected through VC)
3. Dr Ajay Sachan [Nominee of the Drugs Controller General (I), CDSCO, New Delhi]
4. Mr. A. K. Pradhan [Nominee of the Drugs Controller General (I), CDSCO, New Delhi] (connected through VC)
5. Dr. D. Srinivasa Reddy, Director, IICT, Hyderabad (connected through VC)
6. Dr. Hemant Koshia, Commissioner, Food and Drug Control Administration, Ahmedabad
7. Dr. A. K. Singh, Former Director General(LS), DRDO, New Delhi (connected through VC)
8. Dr. Bikash Medhi, Dept. of Pharmacology, PGIMER, Chandigarh
9. Prof. Sanjeev Sinha, Dept. of Medicine, AIIMS, New Delhi (connected through VC)
10. Dr. Arvind K. Bansal, Deptt. of Pharmaceutics, NIPER, Mohali
11. Dr. Inder Pal Singh, Dept. of Natural Products, NIPER, Mohali (connected through VC)
12. Dr. C. Hariharan, Director, CDTL, Mumbai (connected through VC)
13. Dr. Sunil Gairola, Executive Director, Serum Institute, Pune(connected through VC)
14. Dr. Anil Kumar Tyagi, Chief Scientific Officer, Mankind Pharma Ltd., New Delhi
15. Sh. Zoher Sihorwala, Head-Global Regulatory Affairs, Wockhardt, Aurangabad (connected through VC)
16. Dr. V. Kalaiselvan, Secretary-cum-Scientific Director-IPC and Member Secretary

Leave of Absence

1. Dr. Amulya K. Panda, Former Director, NII, Delhi
2. Dr. N. Bhaskar, Advisor (Science and Standards), FSSAI, New Delhi
3. Dr. D. J. Kalita, Head-Technical and Regulatory, Zenex Animal Health India Pvt. Ltd., Ahmedabad
4. Dr. Ravi P. Singh, Provost. Adani University, Ahmedabad
5. Sh. D. R. Gahane, Joint Commissioner, Food and Drugs Administration, Mumbai
6. Dr. Naresh Bhatnagar, Dept. of Mechanical Eng., IIT, Delhi